Coronavirus research

Spain

The epidemic –now pandemic– of the new coronavirus is advancing at a staggering pace. Fortunately, the scientific studies and evidence on the virus (SARS-CoV-2) and the disease (COVID-19) are also advancing at great speed.  

Funded thanks to:
  • Donors
  • Total raised
    76%raised
    • Nicequest clients 21.497€
  • Direct beneficiaries 200

    Those people who have naturally benefited from the project's interventions.

  • Indirect beneficiaries 5.000

    Those identifiable people who will potentially recieve an effect from the project's activities.

ISGlobal

Budget

  • Materials 28.000€
  • Total 28.000€
28.000€

Description

Hundreds of thousands of people have been diagnosed with COVID-19. The SARS-CoV-2 virus, named after the pneumonia outbreak that erupted in December 2019 in Wuhan, China, is responsible for the disease. To date, this virus in the Coronaviridae family has spread to many countries, affecting Asia, Africa, Europe and the Americas, and has been declared a pandemic by the World Health Organization.

In addition to mitigating the morbidity and mortality associated with COVID-19, in outbreaks like this, preventing the appearance of so-called "secondary cases" is an essential strategy. These secondary cases refer to people who are infected by direct contact with patients with the disease - health personnel and family members, mainly. In addition to perpetuating the spread of the disease, infection by healthcare professionals poses a serious problem in healthcare settings.

The objective of this project is to break the coronavirus transmission chain by using existing medication. The team led by researchers from the Institute for Global Health (ISGlobal) and the Hospital Clínic will explore the efficacy of medicines already on the market to prevent new infections and protect the population at risk, especially health workers and people who are in contact with cases affected by SARS-CoV-2.

Activities

  • Test the efficacy of other antiviral drugs onin the market is currently being tested. 
  • Conduct clinical assays to test the efficacy of new treatments.

Who will benefit?

Patients affected by COVID-19 across the world.

Project objectives

Find medication to prevent new COVID-19 infections and protect the population at risk from already marketed medication

Updates & Links

ISGlobal (web)

This website uses cookies. If you continue browsing we will consider you have accepted their use . Obtain more information.